Alpha 2.0
Login Register
» Authors » G J Kontoghiorghes

G J Kontoghiorghes

Explore the profile of G J Kontoghiorghes including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 74
Citations 969
Followers 0
Related Specialties
General Medicine
Hematology
Biochemistry
Top 10 Co-Authors
A V Hoffbrand
L Sheppard
A N Bartlett
P Nortey
A Kolnagou
J Barr
J G Goddard
P Tondury
B Wonke
H G van Eijk
Published In
Lancet
Br J Haematol
Arzneimittelforschung
Biochim Biophys Acta
FEBS Lett
Affiliations
Soon will be listed here.
Recent Articles
1.
Effective inhibition of copper-catalyzed production of hydroxyl radicals by deferiprone
Timoshnikov V, Kobzeva T, Selyutina O, Polyakov N, Kontoghiorghes G
J Biol Inorg Chem . 2019 Mar; 24(3):331-341. PMID: 30868263
Copper ions can catalyze the production of free oxygen radicals (•OH and •OOH) similar to iron ions. The capacity to initiate oxidative damage is most commonly attributed to Cu-induced toxicity...
2.
Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone
Timoshnikov V, Kobzeva T, Polyakov N, Kontoghiorghes G
Free Radic Biol Med . 2014 Dec; 78:118-22. PMID: 25451643
Deferiprone (L1) is an effective iron-chelating drug that is widely used for the treatment of iron-overload diseases. It is known that in aqueous solutions Fe(2+) and Fe(3+) ions can produce...
3.
A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response
Kontoghiorghes G
Expert Opin Drug Saf . 2013 Oct; 12(5):794-5. PMID: 24137699
No abstract available.
4.
Turning a blind eye to deferasirox's toxicity?
Kontoghiorghes G
Lancet . 2013 Apr; 381(9873):1183-4. PMID: 23561999
No abstract available.
5.
Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases
Kontoghiorghes G, Kolnagou A, Peng C, Shah S, Aessopos A
Expert Opin Drug Saf . 2010 Jan; 9(2):201-6. PMID: 20059374
An increased number of thalassaemia patients treated with effective chelation therapy protocols are achieving body iron levels similar to those of normal individuals. Iron chelation therapy has also been recently...
6.
The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects
Kontoghiorghes G, Pattichis K, Neocleous K, Kolnagou A
Curr Med Chem . 2004 Jul; 11(16):2161-83. PMID: 15279556
Iron is essential for all human cells as well as neoplastic cells and invading microbes. Natural and synthetic iron chelators could affect biological processes involving iron and other metal ions...
7.
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility
Kontoghiorghes G, Kolnagou A
Lancet . 2003 Jan; 361(9352):184. PMID: 12531621
No abstract available.
8.
Molecular factors affecting the complex formation between deferiprone (L1) and Cu(II). Possible implications on efficacy and toxicity
Pashalidis I, Kontoghiorghes G
Arzneimittelforschung . 2002 Jan; 51(12):998-1003. PMID: 11799848
Deferiprone (1,2-dimethyl-3-hydroxypyrid-4-one, L1, CAS 30652-11-0) is a new chelating drug used worldwide for the treatment of iron overloading conditions. Spectrophotometric and potentiometric measurements were carried out to investigate the interaction...
9.
Deferiprone or fatal iron toxic effects?
Kontoghiorghes G, Agarwal M, Tondury P, Marx J
Lancet . 2001 Mar; 357(9259):882-3. PMID: 11265977
No abstract available.
10.
Competition studies of L1-deferiprone with copper and iron. Possible implications on efficacy, toxicity and new therapeutic applications
Pashalidis I, Kontoghiorghes G
Transfus Sci . 2000 Dec; 23(3):259-61. PMID: 11099910
No abstract available.